| abstract |
Use of non-peptide bradykinin antagonists and their salts is claimed to treat chronic fibrogenetic liver disease (liver cirrhosis and liver fibrosis), acute liver disease and to prevent complications. Preferably the non-peptide bradykinin antagonist is a compound of formula (I). D-D' = X3=X2-X1=N, X4-C(R3)=N, N=C(R3)-X4, X4-CO-X4, CR3)=C(R3)-O; E = 1-4C alkyl, 1-4C alkylthio, 1-4C alkoxy (all optionally substituted by F), H, halo etc.; X1-X3 = N or optionally substituted CH; X4 = O, N or NR7; R1, R2 = H, halo, 1-4C alkyl or 1-4C alkoxy; R3 = H, halo, 1-6C alkyl, 6-12C aryl, (1-3C alkyl)(6-12C aryl), 3-5C alkenyl, 1-4C alkoxy, CO2H etc. |